Kornimate/medical-research-clean huggingface dataset:
stem cells in myocardial infarction

Conditions: Acute Myocardial Infarction

Summary: the purpose of this trial is to investigate the effect of treatment with granulocyte-colony stimulating factor (g-csf) bone marrow stimulation on circulating stem cells' ability to develop new blood vessels in the myocardium after an acute myocardial infarction.

intracoronary infusion of bone-marrow stem cells after a st elevation myocardial infarction (stemi) seems to improve cardiac function. an alternative strategy is increase of circulating stem cells by mobilisation from the bone marrow with granulocyte-colony stimulating factor (g-csf). objective: to determine the short-term (30 days) safety of g-csf therapy after a stemi treated with acute percutaneous coronary intervention (pci). methods: patients with stemi treated with pci \ 100 microgram/l. follow-up was done after 1, 5 and 6 months, with an angiogram at 5 months.

Eligibility criteria:
inclusion criteria: * patients between 20 and 70 years with stemi were eligible if they had a successful pci within 12 hours after onset of symptoms. * the target lesion had to be located in the proximal section of the left anterior descending (lad), left circumflex (lcx) or right coronary artery (rca). * only patients with creatine kinase \[ck\]-mb \>100 microgram/l or development of q waves in the electrocardiogram were included. exclusion criteria: * ventricular arrhythmia after pci requiring treatment * pregnancy * unprotected left main stem lesion * history of prior myocardial infarction * diagnosed or suspected cancer * new york heart association (nyha) class 3-4 * known severe claustrophobia * significant stenosis in another coronary vessel than the acutely treated vessel, that might demand treatment with pci or coronary artery bypass graft surgery (cabg) prior to the last follow-up exam.

Keywords: st-elevation myocardial infarction granulocyte-colony stimulating factor angiogenesis stem cells
efficacy of five strategies to improve stroke awareness in the spanish-speaking population

Conditions: Stroke Acute

Summary: the goal of this experimental study is to evaluate the efficacy of five educational strategies for recognizing early symptoms of cerebrovascular disease (cvd) in the general adult population. the main questions it aims to answer are: - how effective are the strategies rapido, corre, dale, camaleon, and ictus 911 in improving the recognition of early cvd symptoms? researchers will compare these strategies to determine which one leads to the highest increase in symptom recognition. participants will receive a brief educational session on one of the five strategies and will: * complete a pre- and post-intervention survey (stroke awareness questionnaire, saq). * receive short training on cvd symptoms and the urgency of contacting emergency services. the primary outcome is the improvement in saq scores, and the secondary outcome is the proportion of participants achieving adequate knowledge of cvd symptoms.


Eligibility criteria:
inclusion criteria: * age: participants must be 18 years or older. * consent: participants must provide informed consent to participate in the study. * general population: participants from the general public, regardless of their health insurance status or previous medical history (except as specified in exclusion criteria). * language: participants must be fluent in spanish, as the educational interventions are based on spanish-language mnemonic strategies. exclusion criteria: * history of stroke: participants with a previous diagnosis of cerebrovascular disease (stroke) will be excluded. * cognitive impairment: participants who are unable to understand or complete the stroke awareness questionnaire (saq) due to cognitive or communication impairments will not be eligible. * incomplete evaluation: participants who are unable to complete both the pre- and post-intervention assessments will be excluded from the study. elimination criteria: * lack of follow-up: participants who fail to attend the second evaluation (7 days post-intervention) will be excluded from the final analysis. * withdrawal of consent: participants who choose to withdraw from the study at any time will be eliminated from further participation.

Keywords: stroke symptom recognition mnemonic-based education stroke awareness spanish-speaking population public health intervention
dual trigger to reduce ovarian hyperstimulation syndrome

Conditions: Infertility and at High Risk of OHSS

Summary: gonadotropin releasing hormone (gnrh) agonist is sufficient for triggering final oocyte maturation in gnrh antagonist protocol and can significantly reduce incidence of ovarian hyperstimulation syndrome (ohss) in high-risk patients. however, lower oocyte yield was reported in patients with lower luteinizing hormone (lh) level post trigger with single injection of gnrh agonist, which might be related to the shorter duration and lower amount of lh induced by gnrh agonist. our aim is to study dual trigger with gnrh agonist and human chorionic gonadotropin (hcg) for preventing ohss and maintaining clinical outcome in high risk patients who receive controlled ovarian stimulation in gnrh antagonist protocol.


Eligibility criteria:
inclusion criteria: * patients with polycystic ovarian syndrome * patients with polycystic ovarian morphology on ultrasound * patients who previously experienced an ovarian stimulation cycle, with a high response to gonadotrophins exclusion criteria: * patients undergoing coasting * patients with past ovarian surgery

Keywords: ovarian hyperstimulation syndrome luteinizing hormone polycystic ovarian syndrome ovarian yield ovarian maturity gonadotropin releasing hormone agonist human chorionic gonadotropin
crystalille cohort: getting the whole picture of crystal-related arthropathies

Conditions: Gout; Chondrocalcinosis; Hydroxyapatite

Summary: the objective of this research is to collect data to create an observatory of microcrystalline rheumatism (gout and calcium-crystal rheumatism) in patients treated at the groupement des hôpitaux de l'institut catholique de lille, in order to better understand the disease and improve patient care, in particular with the help of medical imaging.

all patients already included in another observational study set up in 2016 and meeting the eligibility criteria may be included in this study. an information letter will be sent to them by mail. if they wish to oppose to the use of their data, they can then return the objection form. this sample will be supplemented by new patients who are recruited during a classic rheumatology consultation. the investigator will propose the study to all patients meeting the inclusion and non-inclusion criteria. they will be informed of the objectives of the study and their rights. for patients who agree to participate in the study, sociodemographic and clinical characteristics will be collected. depending on the usual care, they will benefit from an ultrasound and/or a dual energy scanner (m0). imaging data will be collected. routine clinical follow-up is then carried out in consultation, with collection of clinical and biological evolution data, and morphological data if necessary if imaging is rechecked, until the patient is lost to follow-up or the follow-up is interrupted at the ghicl for any reason. available quarterly or semi-annual data will be collected.

Eligibility criteria:
inclusion criteria: * diagnosis of gout according to american college of rheumatology /european league against rheumatism (acr/eular) 2015 criteria or diagnosis of calcium pyrophosphate dihydrate crystal deposition disease (cppd) based on eular 2011 recommendations or diagnosis of hydroxyapatite crystal rheumatism (hcr) according to a typical clinical sequence and demonstration of compatible calcium deposits on imaging * patient who will benefit or has benefited from an ultrasound and/or dect evaluation of microcrystalline deposits * clinical suspicion of microcrystalline rheumatism requiring further imaging to confirm the diagnosis exclusion criteria: * refusal or contra-indication to perform ultrasound or dual energy scanning. * patient's opposition to the use of his or her health data for research purposes * patient under guardianship or curatorship * pregnant woman * person not affiliated to a social security scheme or entitled to a social security benefit

Keywords: gout chondrocalcinosis hydroxyapatite
a morbidity-mortality and remodeling study with valsartan

Conditions: Hypertension; Ischemic Heart Disease; Congestive Heart Failure

Summary: the jikei heart study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin ii receptor blocker (arb), in addition to conventional treatment, will improve the prognosis of 3000 japanese patients with cardiovascular diseases.

several recent clinical trials have demonstrated that angiotensin ii receptor blockers (arbs) have cardiovascular as well as renal protective effects. however, it is a problem that the number of asian patients is very little in these trials. the researchers examine the treatment meaning by arb about the prognosis of the patient who amalgamates either among high blood pressure, the ischemic heart disease, and congestive heart failures.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of hypertension, ischemic heart disease and congestive heart failure exclusion criteria: * pregnancy * severe renal damage * severe liver damage * acute myocardial infarction

Keywords: stroke myocardial infarction angina renal damage
agreement and precision study

Conditions: Eye Abnormalities; Normal Eyes

Summary: to evaluate the performance of pachymetry function


Eligibility criteria:
inclusion criteria: * provide voluntary written consent * age at least 22 years old * for glaucoma group only, visual field defect and optic nerve damage consistent with glaucoma * for cornea group only, cornea abnormality exclusion criteria: * ocular condition that may affect ability to perform cornea measurements * have or is suspected to have ocular infection * unable to tolerate eye testing
safety and immunogenicity of pneumococcal conjugate formulations in healthy adults 18 through 49 years of age

Conditions: Pneumococcal Disease

Summary: the purpose of the study is to describe the safety and immunogenicity of pneumococcal conjugate formulations in healthy adults 18 through 49 years of age.


Eligibility criteria:
inclusion criteria: * male or female participants ≥18 and ≤49 years of age at the time of consent * adults determined by clinical assessment to be eligible for the study, including adults with preexisting stable disease within 12 weeks before receipt of study intervention * participants willing to use acceptable contraception for at least 28 days after study intervention; female participants not of childbearing potential; male participants unable to father children exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction to any component in pneumococcal conjugate vaccines and any other diphtheria toxoid-containing vaccine * serious chronic disorder that in the investigator's opinion would make the participant inappropriate for entry into the study * medical or psychiatric condition (recent or active suicidal ideation/behavior or laboratory abnormality) that may increase risk of study participation or make participant inappropriate for the study * known or suspected immunodeficiency or other conditions associated with immunosuppression * previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt of any licensed or investigational pneumococcal vaccine through study participation * receipt of any inactivated or otherwise nonlive vaccine within 14 days or any live vaccine within 28 days before administration of study intervention
assessment of plasma and ngal for the early prediction of acute kidney injury after cardiac surgery in adults study

Conditions: Acute Kidney Injury (AKI); Chronic Kidney Disease (CKD); End Stage Renal Disease (ESRD); Estimated Glomerular Filtration Rate (eGFR); Neutrophil Gelatinase-associated Lipocalin (NGAL); Serum Creatinine (SCr); Urine Creatinine (UCr); Urine Albumin (UAlb)

Summary: the study aims to recruit 156 (54 acute kidney injury (aki);102 non-aki) patients undergoing cardio pulmonary bypass (cpb) surgery, including those with chronic kidney disease (ckd) and multiple co-morbidities. urine and blood samples collected pre-operatively and then 0, 3, 6 and 18 hours post-cpb will be stored at -80oc until batch analysed for ngal using the abbott and bioporto assays. aki - defined as a ≥50% rise in serum creatinine (scr) over baseline, or the requirement for renal replacement therapy (rrt). scr will be measured pre-operatively (baseline), then 12 hourly for the first 48 hrs post-cpb and thereafter 24 hourly for 5 days. clinical data collected will include patient demographics, co-morbidities, drug history, pre-operative renal function, surgery details (type, length, cpb time etc.), length of intensive treatment unit and hospital stay and post-operative complications. data will then be analysed comparing the two ngal tests to find out which is superior, whether it is better to use blood or urine and to define optimal ngal cut-offs and sample timing for predicting aki. both the abbott and bioporto assays will subject to a laboratory method evaluation prior to the analysis of any patient specimens in order to verify that their performance is acceptable and meets the manufacturer's claims. this will involve measuring the standard parameters used to assess laboratory assay performance e.g. imprecision (reproducibility), linearity, recovery and method comparison etc.


Eligibility criteria:
inclusion criteria: * adult patients undergoing cardiac surgery, * including patients with both normal renal function (egfr \>60 ml/min) and pre-operative ckd (egfr \< 60 ml/min), * include patients with other existing co-morbidity (e.g. diabetes, vascular disease, hypothyroidism) plus those with risk factors of aki e.g. nephrotoxic drugs. exclusion criteria: * patients already on renal replacement therapy (rrt) * post-renal transplant patients * emergency surgery * patients \<18 yrs of age * pregnancy * patients already involved with other on-going clinical studies

Keywords: cardio-pulmonary bypass (cpb) renal replacement therapy (rrt) enzyme-linked immunosorbent assay (elisa)
impact of reduction of dust mite allergenic load on step down of inhaled corticosteroids in stable asthma

Conditions: Asthma

Summary: eviction methods for dust mite allergy have been evaluated in asthma control in a recent cochrane meta-analysis. none have shown efficacy on asthma control and there are not recommended. the purpose is to evaluate the efficacy of a new commercialized system (acar'up) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

eviction methods for dust mite allergy have been evaluated in asthma control in a recent cochrane meta-analysis. none have shown efficacy on asthma control and there are not recommended. the purpose is to evaluate the efficacy of a new commercialized system, acar'up (a spray pulverized on a technical textile that traps the dust mite) to decrease dust mite load and to assess its impact on the possibility to perform inhaled corticosteroids step down in stable asthmatics.

Eligibility criteria:
inclusion criteria: * confirmed asthma diagnosis * controlled asthma for more than 3 months * treatment with inhaled corticosteroids * dust mite allergy proved by skin tests ou specific immunoglobulin e exclusion criteria: * chronic obstructive pulmonary disease, bronchiectasis, fibrosis, tuberculosis * asthma-chronic obstructive pulmonary disease overlap syndrome * ongoing desensitization for dust mite * pregnancy * previous use of acar'up
online prenatal trial in mindfulness sleep management

Conditions: Pregnancy Related; Insomnia; Depression

Summary: the aim of this study is to assess an online mindfulness intervention for pregnant women (6 weeks) for the treatment of insomnia and prevention of depression relapse in pregnancy. this mindfulness intervention will also be compared with an online intervention (6 weeks) consisting only of education about insomnia in pregnancy. the principal hypothesis is that the mindfulness intervention will be more effective than the education-only intervention.

the aim of this study is to assess an online mindfulness intervention for pregnant women (6 weeks) for the treatment of insomnia and prevention of depression relapse in pregnancy. there will be two groups: 1. an online mindfulness intervention for pregnant women (6 weeks) that focuses on behaviors to overcome sleep difficulties in pregnancy. 2. an online control group that will receive information about sleep in pregnancy (6 weeks). each group will be composed of 25 participants with a total sample of 50. the principal hypothesis is that the mindfulness intervention will be more effective than sleep education in the improvement of sleep and depression symptoms during pregnancy. the differences between the intervention and control group will be analyzed. the acceptability and usability of online content will also be assessed.

Eligibility criteria:
inclusion criteria: 1) viable pregnancy in second trimester (up to 28 weeks gestation); 2) prior diagnosis of depression currently in remission (score \ 7 on the insomnia severity index); 4) age 18 or older; 5) access to an internet-enabled smartphone, tablet, or computer; and 6) english fluency. participants will not be excluded from participation if they are currently receiving psychotropic medications or psychotherapy. exclusion criteria: 1) known severe congenital fetal anomalies, fetal demise, or expected neonatal death; 2) diagnosis of major depressive disorder within past 2 months; 3) other significant psychiatric illness requiring treatment; 4) current hospitalization; 5) prior diagnosis of obstructive sleep apnea or restless leg syndrome; 6) positive self-report screen for restless leg syndrome; 7) regular mindfulness or meditative practice (at least weekly); and 8) regular night-shift work.

Keywords: sleep pregnancy insomnia depression mindfulness
immunophenotype of pbmc to early predict response to immunotherapy in hepatocellular carcinoma

Conditions: Liver Cancer, Adult

Summary: the study is aimed to test the performance of a simple, easy, reproducible cytofluorimetric assay to complement imaging studies for: * predicting response to immune-therapeutic regimens in hcc in the early phase of treatment, * to rule out pseudo-progression, * to early predict the escape from effectiveness of treatment.

* to assess the accuracy of biomarkers from an immunophenotypic test (cd8+, pd1+, pd-l1+, ctla4+, lag3+, cd8+pd1+, cd8+pdl1+ peripheral lymphocyte populations and circulating granulocytes) in predicting the response to immuno-therapy in patients affected by hepatocellular carcinoma (hcc). * to compare the transcriptomic signatures of peripheral blood mononuclear cells (pbmc) of responders and non-responders (assessed at the first imaging study). rnaseq data will be validated by rt-pcr in independent prospective cohorts.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * diagnosis of hcc * execution of laboratory tests and subsequent treatments and follow-up at our center. * obtained written informed consent to the study participation exclusion criteria: * immune-related concomitant diseases * hiv infection

Keywords: immunophenotype hcc patients immunotherapy
delivering telemetry-triggered educational content using mychart in mood disorders

Conditions: Bipolar Disorder; Mood Disorders

Summary: mood disorders - principally major depressive disorder and bipolar disorder - are a significant public health issue affecting one in four people during their lives in total, over 8 million canadians are affected by mood disorders, costing the economy over $6 billion annually. at sunnybrook, 75% of inpatient mental health admissions are due to mood disorders. mood disorders are generally recurrent: approximately half of depression is recurrent; chronic bipolar disorder is typical. use of ratings scales by patients and clinicians to track symptoms has also been shown to enhance outcomes such as remission, medication adherence, and patient engagement. education is considered a key component of treating mood disorders. however, which educational information is useful can vary: in depression, changes in illness severity have been shown to affect what information is absorbed, and timing is also important.to address this, this project will deliver, for the first time ever, a system for using data from patients with mood disorders' electronic mood journals, integrated into sunnybrook's "mychart" personal health record system, to drive just-in-time delivery of educational interventions, using feedback from users to maximize its usefulness.

this project will integrate mood-journaling software ("mht") developed here at sunnybrook (shsc) into shsc's "mychart" patient portal system. next, using alternating expert input and input from focus groups of patients, we will develop a library of educational content and rules to select and drive delivery of content that will, for the first time, allow patients with mood disorders to receive customized, just-in-time educational content using their own self-report data to drive selection and timing of the delivery of the content. while we expect that this innovation should be beneficial to its users, we cannot assess this without adequate numbers of users. so, in this project, we will make this system available to mychart users for six months and collect ongoing feedback on user satisfaction, continuously refining the system over the six months with the goal of steadily increasing the number of users frequently using this system.

Eligibility criteria:
inclusion criteria: i) registered user of sunnybrook health sciences centre "mychart" electronic patient portal exclusion criteria: -

Keywords: mental health information technology chronic disease prevention and management support patient self-care